Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “mTOR”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Ended earlyNCT00742105
What this trial is testing

Phase I Study to Determine the Maximum Tolerate Dose (MTD) of BGT226 in Advanced Solid Tumors in Japan

Who this might be right for
CancerSolid TumorAdvanced Solid Tumor
Novartis Pharmaceuticals 18
Not applicableNot Yet RecruitingNCT07387861
What this trial is testing

PI3K Pathway Activation Markers in ER-Positive, HER2-Negative Breast Cancer: A Clinicopathologic Study

Who this might be right for
Breast Cancer - ER+, HER2-, PIK3CA Gene Mutation
Assiut University 70
Testing effectiveness (Phase 2)Study completedNCT00378703
What this trial is testing

Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer

Who this might be right for
Clear Cell Renal Cell CarcinomaRecurrent Renal Cell CarcinomaStage IV Renal Cell Cancer AJCC v7
National Cancer Institute (NCI) 361
Testing effectiveness (Phase 2)Study completedNCT03433183
What this trial is testing

SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors

Who this might be right for
Malignant Peripheral Nerve Sheath TumorsNeurofibromatosis 1
Sarcoma Alliance for Research through Collaboration 21
Testing effectiveness (Phase 2)Study completedNCT02451696
What this trial is testing

A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCD

Who this might be right for
EpilepsyTuberous Sclerosis ComplexFocal Cortical Dysplasia
NYU Langone Health 15
Not applicableStudy completedNCT01338090
What this trial is testing

89Zr-bevacizumab PET Imaging in Patients With Neuroendocrine Tumors

Who this might be right for
Neuroendocrine Tumors
University Medical Center Groningen 14
Early research (Phase 1)Active Not RecruitingNCT05508906
What this trial is testing

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

Who this might be right for
Metastatic Breast CancerER-positive Breast CancerHER2-negative Breast Cancer+2 more
Olema Pharmaceuticals, Inc. 190
Post-approval studies (Phase 4)Study completedNCT03525834
What this trial is testing

Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex.

Who this might be right for
Renal Angiomyolipoma
Novartis Pharmaceuticals 40
Testing effectiveness (Phase 2)Study completedNCT02831257
What this trial is testing

AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas

Who this might be right for
Neurofibromatosis 2Meningioma
Massachusetts General Hospital 18
Not applicableNot Yet RecruitingNCT07767877
What this trial is testing

Clinical Practice and Real-world Care of Patients Treated With mTOR, PI3K, and MEK Inhibitors for Extracranial Vascular Anomalies

Who this might be right for
Vascular Anomalies
Novartis Pharmaceuticals 200
Not applicableLooking for participantsNCT05235464
What this trial is testing

High Protein Diet and Atherosclerosis

Who this might be right for
Atherosclerosis
University of Missouri-Columbia 24
Early research (Phase 1)Study completedNCT01343498
What this trial is testing

Study of PI3 Kinase/mTOR Inhibitor BEZ235 Twice Daily for Advanced Solid Tumors

Who this might be right for
Malignant Solid Tumour
SCRI Development Innovations, LLC 33
Testing effectiveness (Phase 2)Study completedNCT01620307
What this trial is testing

Rapamune Improves Outcomes of Severe H1N1 Pneumonia

Who this might be right for
H1N1 PneumoniaHypoxemia
Chang Gung Memorial Hospital 38
Testing effectiveness (Phase 2)UnknownNCT03745911
What this trial is testing

Paclitaxel and TAK-228 in Urothelial Carcinoma

Who this might be right for
Metastatic Urothelial Cancer
Associació per a la Recerca Oncologica, Spain 52
Testing effectiveness (Phase 2)Study completedNCT00736970
What this trial is testing

Oral Deforolimus With Trastuzumab for Patients With HER2-positive Trastuzumab-Refractory Metastatic Breast Cancer (8669-009)

Who this might be right for
Breast CancerBreast Neoplasms
Merck Sharp & Dohme LLC 34
Early research (Phase 1)Active Not RecruitingNCT02208375
What this trial is testing

MTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian

Who this might be right for
BRCA1 Mutation CarrierBRCA2 Mutation CarrierEndometrial Adenocarcinoma+13 more
M.D. Anderson Cancer Center 159
Post-approval studies (Phase 4)Study completedNCT01935128
What this trial is testing

Evaluation of Calcineurin-inhibitor Reduction With Conversion at 2 Months to Everolimus/Reduced Tacrolimus in Renal Transplant Recipients Following Campath® Induction

Who this might be right for
Renal Transplant
University of Toledo Health Science Campus 55
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07680322
What this trial is testing

The Safety and Efficacy of AV078 in Participants With Tuberous Sclerosis Complex (TSC) Refractory Epilepsy

Who this might be right for
Tuberous Sclerosis ComplexEpilepsy
Aeovian Pharmaceuticals, Inc. 42
Not applicableStudy completedNCT02444390
What this trial is testing

Molecular Alterations Associated With Resistance to Endocrine Therapy and Impacting Treatment With mTOR Inhibitor

Who this might be right for
Metastatic Breast Cancer
UNICANCER 150
Very early researchLooking for participantsNCT07095933
What this trial is testing

The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy

Who this might be right for
EpilepsyDrug Resistant
Xuanwu Hospital, Beijing 5
Next Page